Low-penetrance susceptibility variants in familial colorectal cancer. 2010

Iina Niittymäki, and Eevi Kaasinen, and Sari Tuupanen, and Auli Karhu, and Heikki Järvinen, and Jukka-Pekka Mecklin, and Ian P M Tomlinson, and Maria Chiara Di Bernardo, and Richard S Houlston, and Lauri A Aaltonen
Department of Medical Genetics, Genome-Scale Biology Research Program, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland.

BACKGROUND Genomewide association studies have identified 10 low-penetrance loci that confer modestly increased risk for colorectal cancer (CRC). Although they underlie a significant proportion of CRC in the general population, their impact on the familial risk for CRC has yet to be formally enumerated. The aim of this study was to examine the combined contribution of the 10 variants, rs6983267, rs4779584, rs4939827, rs16892766, rs10795668, rs3802842, rs4444235, rs9929218, rs10411210, and rs961253, on familial CRC. METHODS The population-based series of CRC samples included in this study consisted of 97 familial cases and 691 sporadic cases. Genotypes in the 10 loci and clinical data, including family history of cancer verified from the Finnish Cancer Registry, were available. The overall number of risk alleles (0-20) was determined, and its association with familial CRC was analyzed. Excess familial risk was estimated using cancer incidence data from the first-degree relatives of the cases. RESULTS A linear association between the number of risk alleles and familial CRC was observed (P = 0.006). With each risk-allele addition, the odds of having an affected first-degree relative increased by 1.16 (95% confidence interval, 1.04-1.30). The 10 low-penetrance loci collectively explain approximately 9% of the variance in familial risk for CRC. CONCLUSIONS This study provides evidence to support the previous indirect estimations that these low-penetrance variants account for a relatively small proportion of the familial aggregation of CRC. CONCLUSIONS Our results emphasize the need to characterize the remaining molecular basis of familial CRC, which should eventually yield in individualized targeting of preventive interventions.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005192 Family Health The health status of the family as a unit including the impact of the health of one member of the family on the family as a unit and on individual family members; also, the impact of family organization or disorganization on the health status of its members. Health, Family
D005260 Female Females
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor

Related Publications

Iina Niittymäki, and Eevi Kaasinen, and Sari Tuupanen, and Auli Karhu, and Heikki Järvinen, and Jukka-Pekka Mecklin, and Ian P M Tomlinson, and Maria Chiara Di Bernardo, and Richard S Houlston, and Lauri A Aaltonen
November 2009, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology,
Iina Niittymäki, and Eevi Kaasinen, and Sari Tuupanen, and Auli Karhu, and Heikki Järvinen, and Jukka-Pekka Mecklin, and Ian P M Tomlinson, and Maria Chiara Di Bernardo, and Richard S Houlston, and Lauri A Aaltonen
November 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology,
Iina Niittymäki, and Eevi Kaasinen, and Sari Tuupanen, and Auli Karhu, and Heikki Järvinen, and Jukka-Pekka Mecklin, and Ian P M Tomlinson, and Maria Chiara Di Bernardo, and Richard S Houlston, and Lauri A Aaltonen
January 2020, Journal of genetics,
Iina Niittymäki, and Eevi Kaasinen, and Sari Tuupanen, and Auli Karhu, and Heikki Järvinen, and Jukka-Pekka Mecklin, and Ian P M Tomlinson, and Maria Chiara Di Bernardo, and Richard S Houlston, and Lauri A Aaltonen
December 2013, Human molecular genetics,
Iina Niittymäki, and Eevi Kaasinen, and Sari Tuupanen, and Auli Karhu, and Heikki Järvinen, and Jukka-Pekka Mecklin, and Ian P M Tomlinson, and Maria Chiara Di Bernardo, and Richard S Houlston, and Lauri A Aaltonen
January 2012, PloS one,
Iina Niittymäki, and Eevi Kaasinen, and Sari Tuupanen, and Auli Karhu, and Heikki Järvinen, and Jukka-Pekka Mecklin, and Ian P M Tomlinson, and Maria Chiara Di Bernardo, and Richard S Houlston, and Lauri A Aaltonen
January 2009, Journal of the National Cancer Institute,
Iina Niittymäki, and Eevi Kaasinen, and Sari Tuupanen, and Auli Karhu, and Heikki Järvinen, and Jukka-Pekka Mecklin, and Ian P M Tomlinson, and Maria Chiara Di Bernardo, and Richard S Houlston, and Lauri A Aaltonen
October 2006, BJU international,
Iina Niittymäki, and Eevi Kaasinen, and Sari Tuupanen, and Auli Karhu, and Heikki Järvinen, and Jukka-Pekka Mecklin, and Ian P M Tomlinson, and Maria Chiara Di Bernardo, and Richard S Houlston, and Lauri A Aaltonen
February 2021, Clinical and translational gastroenterology,
Iina Niittymäki, and Eevi Kaasinen, and Sari Tuupanen, and Auli Karhu, and Heikki Järvinen, and Jukka-Pekka Mecklin, and Ian P M Tomlinson, and Maria Chiara Di Bernardo, and Richard S Houlston, and Lauri A Aaltonen
January 2005, Lancet (London, England),
Iina Niittymäki, and Eevi Kaasinen, and Sari Tuupanen, and Auli Karhu, and Heikki Järvinen, and Jukka-Pekka Mecklin, and Ian P M Tomlinson, and Maria Chiara Di Bernardo, and Richard S Houlston, and Lauri A Aaltonen
August 2004, Oncogene,
Copied contents to your clipboard!